Harstrick A, Casper J, Schmoll H J
Int J Androl. 1987 Feb;10(1):139-45. doi: 10.1111/j.1365-2605.1987.tb00175.x.
The comparative antitumour activity of cisplatin, JM8 and JM9 was tested using a panel of different heterotransplanted human testicular tumour cell lines. All drugs were applied at equitoxic doses in a 5 day schedule. In the two cisplatin sensitive cell lines 2102 EP and H 12.1 both analogues were inferior to cisplatin. No significant therapeutic effect was achieved with any of the three drugs in the cisplatin resistant line H 23.1. Thus JM8 and JM9 seem to be less active in cisplatin sensitive tumours and seem to be of no advantage in the case of cisplatin resistance.
使用一组不同的异种移植人睾丸肿瘤细胞系测试了顺铂、JM8和JM9的比较抗肿瘤活性。所有药物均以等毒性剂量按5天疗程给药。在两个顺铂敏感细胞系2102 EP和H 12.1中，两种类似物均不如顺铂。在顺铂耐药细胞系H 23.1中，三种药物均未取得显著治疗效果。因此，JM8和JM9在顺铂敏感肿瘤中似乎活性较低，在顺铂耐药情况下似乎没有优势。
